Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 29;15(1):31824.
doi: 10.1038/s41598-025-17574-1.

Effect of GLP-1RA on coronary progression and cardiovascular outcomes in type 2 diabetic patients after PCI: a prospective cohort study

Huasu Zeng #  1 , Jingchao Hu #  1 , Yang Zhuo #  1   2 , Min Wang #  1 , Lin Gao  1 , Zhengde Tang  1 , JunFeng Zhang  1 , Ping Yin  3 , Jun Gu  4 , Changqian Wang  5
Affiliations

Effect of GLP-1RA on coronary progression and cardiovascular outcomes in type 2 diabetic patients after PCI: a prospective cohort study

Huasu Zeng et al. Sci Rep. .

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce incidence of cardiovascular events in type 2 diabetes (T2D) patients. Yet, the impact of GLP-1RAs on coronary lesion progression and cardiovascular outcomes after coronary stent implantation remains unclear. We aimed to investigate the effects of GLP-1RAs on coronary lesion progression and major adverse cardiovascular events (MACEs) after percutaneous coronary intervention (PCI). This prospective cohort study enrolled 1664 patients with T2D who underwent PCI from January 2020 to March 2024. Matched GLP-1RAs-treated and non-treated cohorts were formed using the propensity score matching method. The primary endpoint was the incidence of MACEs (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure). Secondary endpoints included in-stent restenosis and non-target lesion progression. Two 131-patient cohorts with balanced baseline characteristics were formed by propensity score matching. During the median follow-up period of 20 months (ranging from 6 to 48 months), the incidence of MACEs was significantly lower in the GLP-1RA group (7.63%)compared to the control group (19.85%) (HR 0.444; 95%CI, 0.215-0.918; P = 0.024). During a median follow-up period of 12 months, 79.39% (104/131) of patients in the control group and 82.44% (108/131) of patients in the GLP-1RA group successfully underwent coronary angiography follow-up. The incidence of in-stent restenosis was 2.78% (3/108) in the GLP-1RA group and 11.54% (12/104) in the control group (P = 0.028). Non-target lesion progression was found in 10.19% (11/108) patient of the GLP-1RA group and 22.12% (23/104) in the control group (P = 0.037). Notable disparities were observed between the two groups regarding improvements of BMI, SBP, HbA1c, LDL-C, CRP. GLP-1RAs significantly reduced the incidence of MACEs and coronary lesion progression in patients with T2D after coronary stent implantation. These findings suggest that GLP-1RAs may have beneficial effects on cardiovascular outcomes and coronary artery disease progression in this population.

Keywords: Coronary lesion progression; GLP-1RAs; Major adverse cardiovascular events; Percutaneous coronary intervention; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Study flow chart.
Fig. 2
Fig. 2
Kaplan–Meier (KM) curve.
Fig. 3
Fig. 3
Changes in clinical parameters.*p < 0.05, **p < 0.01, ***p < 0.001.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Włodarczak, A. et al. Mid-term safety and efficacy of magnesium bioresorbable vascular scaffolds-magmaris in diabetic population. 2-Years outcome in acute coronary syndrome cohort. Diab. Vasc. Dis. Res.20(4), 14791641231188704. 10.1177/14791641231188705 (2023). - PMC - PubMed
    1. Ma, Y., Gao, H. & Wu, H. Comparison of adverse cardiovascular event endpoints between patients with diabetes and patients without diabetes based on coronary artery plaques: A systematic review and meta-analysis. J. Cardiothorac. Surg.19(1), 672. 10.1186/s13019-024-03157-0 (2024). - PMC - PubMed
    1. Yagyu, H. & Shimano, H. Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease. J. Diabetes Investig.13(9), 1472–1488. 10.1111/jdi.13859 (2022). - PMC - PubMed
    1. Sivakumar, P. M., Premkumar, B., Prabhawathi, V. & Prabhakar, P. K. Role of GLP-1 analogs in the management of diabetes and its secondary complication. Mini Rev. Med. Chem.21(20), 3166–3182. 10.2174/1389557521666210422114909 (2021). - PubMed
    1. Taha, M. B. et al. Glucagon-like peptide 1 receptor agonists: A medication for obesity management. Curr. Atheroscler. Rep.24(8), 643–654. 10.1007/s11883-022-01041-7 (2022). - PubMed

Substances